Trait Versus State Predictors of Emotional Distress Symptoms: The Role of the Big-5 Personality Traits, Metacognitive Beliefs, and Strategies

Henrik Nordahl, Omid V Ebrahimi, Asle Hoffart, Sverre Urnes Johnson, Henrik Nordahl, Omid V Ebrahimi, Asle Hoffart, Sverre Urnes Johnson

Abstract

To enhance formulation and interventions for emotional distress symptoms, research should aim to identify factors that contribute to distress and disorder. One way to formulate emotional distress symptoms is to view them as state manifestations of underlying personality traits. However, the metacognitive model suggests that emotional distress is maintained by metacognitive strategies directed by underlying metacognitive beliefs. The aim of the present study was therefore to evaluate the role of these factors as predictors of anxiety and depression symptoms in a cross-sectional sample of 4936 participants collected during the COVID-19 pandemic. Personality traits (especially neuroticism) were linked to anxiety and depression, but metacognitive beliefs and strategies accounted for additional variance. Among the predictors, metacognitive strategies accounted for the most variance in symptoms. Furthermore, we evaluated two statistical models based on personality traits versus metacognitions and found that the latter provided the best fit. Thus, these findings indicate that emotional distress symptoms are maintained by metacognitive strategies that are better accounted for by metacognitions compared with personality traits. Theoretical and clinical implications of these findings are discussed.

Trial registration: ClinicalTrials.gov NCT04444505.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Figures

FIGURE 1
FIGURE 1
Structural equation model of the metacognitive model (n = 4936). Circles represent latent variables, and rectangles represent observed variables (indicators). CAS1, worry/rumination; CAS2, threat monitoring; CAS3, maladaptive coping strategies; CAS4A-D, negative metacognitive beliefs.
FIGURE 2
FIGURE 2
Structural equation model of the comparison model that included personality traits (n = 4936). Circles represent latent variables, and rectangles represent observed variables (indicators). CAS1, worry/rumination; CAS2, threat monitoring; CAS3, maladaptive coping strategies; N, neuroticism; E, extraversion; A, agreeableness; C, conscientiousness.

References

    1. Akaike H. (1974) A new look at the statistical model identification. IEEE Trans Automatic Control. 19:716–723.
    1. Aschwanden D, Strickhouser JE, Sesker AA, Lee JH, Luchetti M, Stephan Y, Sutin AR, Terracciano A. (2020) Psychological and behavioural responses to coronavirus disease 2019: The role of personality. Eur J Pers. 35:51–56.
    1. Bailey R, Wells A. (2013) Does metacognition make a unique contribution to health anxiety when controlling for neuroticism, illness cognition, and somatosensory amplification? J Cogn Psychother. 27:327–337.
    1. Bosman RC, Ten Have M, de Graaf R, Muntingh AD, van Balkom AJ, Batelaan NM. (2019) Prevalence and course of subthreshold anxiety disorder in the general population: A three-year follow-up study. J Affect Disord. 247:105–113.
    1. Browne MW, Cudeck R. (1993) Alternative ways if assessing model fit. In Bollen KA, Long JS. (Eds), Testing structural equation models (pp 136–162). Newbury Park, CA: Sage.
    1. Campion J, Javed A, Sartorius N, Marmot M. (2020) Addressing the public mental health challenge of COVID-19. Lancet Psychiatry. 7:657–659.
    1. Chachamovich E, Fleck M, Laidlaw K, Power M. (2008) Impact of major depression and subsyndromal symptoms on quality of life and attitudes toward aging in an international sample of older adults. Gerontologist. 48:593–602.
    1. Claridge G, Davis C. (2001) What's the use of neuroticism? Personal Individ Differ. 31:383–400.
    1. Clauss K, Bardeen JR, Thomas K, Benfer N. (2020) The interactive effect of emotional reactivity and maladaptive metacognitive beliefs on anxiety. Cognit Emot. 34:393–401.
    1. Costa PT, McCrae RR. (1985) The NEO personality inventory. Odessa, FL: Psychological Assessment Resources.
    1. Daly M, Sutin AR, Robinson E. (2020) Longitudinal changes in mental health and the COVID-19 pandemic: Evidence from the UK household longitudinal study. Psychol Med. 1–10. doi:10.1017/S0033291720004432.
    1. Dear BF, Titov N, Sunderland M, McMillan D, Anderson T, Lorian C, Robinson E. (2011) Psychometric comparison of the Generalized Anxiety Disorder Scale-7 and the Penn State Worry Questionnaire for measuring response during treatment of generalised anxiety disorder. Cogn Behav Ther. 40:216–227.
    1. Ebrahimi OV, Hoffart A, Johnson SU. (2021) Physical distancing and mental health during the COVID-19 pandemic: Factors associated with psychological symptoms and adherence to pandemic mitigation strategies. Clin Psychol Sci. 9:489–506.
    1. Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. (2020) Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open. 3:e2019686.
    1. Greenberg PE, Birnbaum HG. (2005) The economic burden of depression in the US: Societal and patient perspectives. Expert Opin Pharmacother. 6:369–376.
    1. Haller H, Cramer H, Lauche R, Gass F, Dobos GJ. (2014) The prevalence and burden of subthreshold generalized anxiety disorder: A systematic review. BMC Psychiatry. 14:128.
    1. Holmes EA, O'Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, Bullmore E. (2020) Multidisciplinary research priorities for the COVID-19 pandemic: A call for action for mental health science. Lancet Psychiatry. 7:547–560.
    1. Hu LT, Bentler PM. (1999) Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equ Model Multidiscip J. 6:1–55.
    1. Jacobson NC, Newman MG. (2017) Anxiety and depression as bidirectional risk factors for one another: A meta-analysis of longitudinal studies. Psychol Bull. 143:1155–1200.
    1. Johansson R, Carlbring P, Heedman Å, Paxling B, Andersson G. (2013) Depression, anxiety and their comorbidity in the Swedish general population: Point prevalence and the effect on health-related quality of life. PeerJ. 1:e98.
    1. Johnson SU, Ulvenes PG, Øktedalen T, Hoffart A. (2019) Psychometric properties of the general anxiety disorder 7-item (GAD-7) scale in a heterogeneous psychiatric sample. Front Psychol. 10:1713.
    1. Kennair LEO, Solem S, Hagen R, Havnen A, Nysæter TE, Hjemdal O. (2021) Change in personality traits and facets (revised NEO personality inventory) following metacognitive therapy or cognitive behaviour therapy for generalized anxiety disorder: Results from a randomized controlled trial. Clin Psychol Psychother. 28:872–881.
    1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 62:593–602.
    1. Kotov R, Gamez W, Schmidt F, Watson D. (2010) Linking “big” personality traits to anxiety, depressive, and substance use disorders: A meta-analysis. Psychol Bull. 136:768–821.
    1. Kroencke L, Geukes K, Utesch T, Kuper N, Back MD. (2020) Neuroticism and emotional risk during the COVID-19 pandemic. J Res Pers. 89:104038.
    1. Kroenke K, Spitzer RL, Williams JB. (2001) The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med. 16:606–613.
    1. Kroenke K, Spitzer RL, Williams JB, Löwe B. (2010) The patient health questionnaire somatic, anxiety, and depressive symptom scales: A systematic review. Gen Hosp Psychiatry. 32:345–359.
    1. Lee SA, Crunk EA. (2022) Fear and psychopathology during the COVID-19 crisis: Neuroticism, hypochondriasis, reassurance-seeking, and coronaphobia as fear factors. Omega (Westport). 85:843–496.
    1. Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, Herzberg PY. (2008) Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. Med Care. 46:266–274.
    1. Magnúsdóttir I, Lovik A, Unnarsdóttir AB, McCartney D, Ask H, Kõiv K, Christoffersen LAN, Johnson SU, Hauksdóttir A, Fawns-Ritchie C, Helenius D, González-Hijón J, Lu L, Ebrahimi OV, Hoffart A, Porteous DJ, Fang F, Jakobsdóttir J, Lehto K, Andreassen OA, Pedersen OBV, Aspelund T, Valdimarsdóttir UA. (2022) Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: An observational study. Lancet Public Health. 7:e406–e416.
    1. Mathers CD, Loncar D. (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3:e442.
    1. Naragon-Gainey K, Watson D. (2018) What lies beyond neuroticism? An examination of the unique contributions of social-cognitive vulnerabilities to internalizing disorders. Assessment. 25:143–158.
    1. Nikčević AV, Spada MM. (2020) The COVID-19 anxiety syndrome scale: Development and psychometric properties. Psychiatry Res. 292:113322.
    1. Nordahl H, Hjemdal O, Hagen R, Nordahl HM, Wells A. (2019) What lies beneath trait-anxiety? Testing the self-regulatory executive function model of vulnerability. Front Psychol. 10:122.
    1. Nordahl H, Wells A. (2019) Measuring the cognitive attentional syndrome associated with emotional distress: Psychometric properties of the CAS-1. Int J Cogn Ther. 12:292–306.
    1. Normann N, Morina N. (2018) The efficacy of metacognitive therapy: A systematic review and Meta-analysis. Front Psychol. 9:2211.
    1. Pietrzak RH, Kinley J, Afifi TO, Enns MW, Fawcett J, Sareen J. (2013) Subsyndromal depression in the United States: Prevalence, course, and risk for incident psychiatric outcomes. Psychol Med. 43:1401–1414.
    1. Rammstedt B, John OP. (2007) Measuring personality in one minute or less: A 10-item short version of the big five inventory in English and German. J Res Pers. 41:203–212.
    1. Saarni SI, Suvisaari J, Sintonen H, Pirkola S, Koskinen S, Aromaa A, Lönnqvist J. (2007) Impact of psychiatric disorders on health-related quality of life: General population survey. Br J Psychiatry. 190:326–332.
    1. Shim RS, Baltrus P, Ye J, Rust G. (2011) Prevalence, treatment, and control of depressive symptoms in the United States: Results from the National Health and Nutrition Examination Survey (NHANES), 2005–2008. J Am Board Fam Med. 24:33–38.
    1. Spitzer RL, Kroenke K, Williams JB, Löwe B. (2006) A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med. 166:1092–1097.
    1. Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, Silove D. (2014) The global prevalence of common mental disorders: A systematic review and meta-analysis 1980–2013. Int J Epidemiol. 43:476–493.
    1. Stevens GA Alkema L Black RE Boerma JT Collins GS Ezzati M, GATHER Working Group (2016) Guidelines for accurate and transparent health estimates reporting: The GATHER statement. PLoS Med. 13:e1002116.
    1. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Ann Intern Med. 147:573–577.
    1. Wells A. (2009) Metacognitive therapy for anxiety and depression. New York: Guilford Press.
    1. Wells A. (2019) Breaking the cybernetic code: Understanding and treating the human metacognitive control system to enhance mental health. Front Psychol. 10:2621.
    1. Wells A, Matthews G. (1994) Attention and emotion: A clinical perspective. Hove: Erlbaum.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner